Cabotegravir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cabotegravir: From HIV-1 Infection to Rheumatoid Arthritis
One-Sentence Summary
Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) approved internationally for HIV-1 treatment and pre-exposure prophylaxis (PrEP), but currently not registered with the TGA for use in Australia. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, however no clinical trials and no publications currently support this repurposing direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (approved internationally; not currently registered in Australia) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Cabotegravir belongs to the integrase strand transfer inhibitor (INSTI) class of antiretrovirals. Its primary mechanism is to block the HIV-1 integrase enzyme, preventing viral DNA from being incorporated into the host cell genome. It is approved in the US, UK, Canada, and other jurisdictions — available as both an oral tablet (Vocabria) and a long-acting injectable formulation (Cabenuva, combined with rilpivirine) — for HIV-1 treatment and PrEP.
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on published pharmacology, some INSTI class drugs have been observed to exert indirect anti-inflammatory effects via NF-κB pathway modulation, which theoretically could have relevance to autoimmune conditions such as rheumatoid arthritis. However, this link is speculative and has not been validated in any RA preclinical or clinical model for Cabotegravir specifically.
The high TxGNN prediction score (99.45%) for rheumatoid arthritis most likely reflects distant comorbidity node associations within the knowledge graph — HIV-infected patients carry elevated rates of systemic autoimmune conditions — rather than a direct, biologically plausible mechanism. No preclinical or clinical evidence currently supports Cabotegravir as a candidate therapy for RA.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Cabotegravir is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no ARTG entries available. Healthcare professionals should refer to international prescribing information (e.g., FDA prescribing information for Vocabria/Cabenuva) for safety and formulation guidance in the interim.
Safety Considerations
Please refer to international Product Information (PI) for safety information, as Cabotegravir does not currently hold TGA registration in Australia. FDA-approved labelling for Vocabria and Cabenuva is available via the FDA website and should be consulted for known warnings, contraindications, and drug interactions.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score, this is an L5 evidence level — model prediction only, with no supporting clinical trials, observational data, or preclinical research for any of the top 10 predicted indications. The proposed mechanistic link between an HIV integrase inhibitor and rheumatoid arthritis pathophysiology is highly speculative, and Cabotegravir is not registered in Australia, adding a significant regulatory barrier before any repurposing pathway can proceed.
To proceed, the following is needed:
- Preclinical studies demonstrating anti-inflammatory or immunomodulatory activity of Cabotegravir in validated RA models (e.g., collagen-induced arthritis)
- Mechanistic clarification: confirmation of whether NF-κB inhibition or other inflammatory pathways are meaningfully engaged at therapeutic drug concentrations
- Full safety baseline via TGA registration or detailed review of international Product Information (PI/SmPC) — including hypersensitivity, hepatotoxicity, and injection site reaction profiles relevant to long-term RA use
- Epidemiological analysis of HIV patient cohorts to distinguish whether the RA signal reflects comorbidity association or a potential therapeutic effect
- At minimum a Phase 2 proof-of-concept trial before committing further resources to this repurposing direction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.